Bristol-Myers Squibb (NY:BMY)

61.46 -0.94 (-1.51%)

Official Closing Price Updated: 4:10 PM EDT, Oct 1, 2026 Add to My Watchlist

Price and Volume

Volume	10,771,897
Open	62.20
Bid (Size)	61.52 (100)
Ask (Size)	61.88 (200)
Prev. Close	62.40
Today's Range	61.25 - 62.61
52wk Range	42.52 - 68.64
Shares Outstanding	2,222,113,553
Dividend Yield	4.10%

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale ↗

Today 15:15 EDT

Johnson & Johnson's revenue base runs roughly double Bristol-Myers Squibb's, with the gap showing signs of widening over the past two years.

Via The Motley Fool

Bristol Myers Squibb Deepens Commitment to Healthcare Professionals Through Champions in Care Movement

Today 6:59 EDT

From Bristol Myers Squibb

Via Business Wire

Performance

YTD	+15.0%	+15.0%
1 Month	-8.0%	-8.0%
3 Month	+8.9%	+8.9%
6 Month	-0.4%	-0.4%
1 Year	+36.3%	+36.3%

More News

U.S. Food and Drug Administration Approves Expanded Indication for Bristol Myers Squibb’s CAMZYOS® (mavacamten) for the Treatment of Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM) in Adults and Pediatric Patients*

September 30, 2026

From Bristol Myers Squibb

Via Business Wire

Q2 Earnings Outperformers: Jazz Pharmaceuticals (NASDAQ:JAZZ) And The Rest Of The Pharmaceuticals Stocks

September 29, 2026

Via StockStory

Bristol Myers Squibb vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 29, 2026

Via The Motley Fool

Here Are My Top 2 High-Yield Healthcare Stocks to Buy Now ↗

September 29, 2026

Via The Motley Fool

3 Numbers That Explain Bristol Myers Squibb's Dirt Cheap Valuation ↗

September 29, 2026

Via The Motley Fool

1 Cash-Producing Stock to Keep an Eye On and 2 Facing Challenges

September 29, 2026

Via StockStory

Bristol Myers Squibb vs. Novo Nordisk: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 27, 2026

Via The Motley Fool

Kevin Warsh Just Signaled Higher-for-Longer Rates. Here's What That Means for Big Pharma Dividend Stocks. ↗

September 27, 2026

Via The Motley Fool

Bristol Myers Squibb Announces First Presentation of Results for ZENBEXUS™ (iberdomide) in Combination with Daratumumab from Phase 3 EXCALIBER-RRMM Trial in Relapsed or Refractory Multiple Myeloma

September 25, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 24, 2026

Via The Motley Fool

Bristol Myers Squibb and Johnson & Johnson Both Face Challenges Ahead: Which Healthcare Stock Looks More Resilient Now? ↗

September 24, 2026

Via The Motley Fool

Wall Street's Bull Case for Bristol Myers Squibb Is Getting Louder ↗

September 20, 2026

Via The Motley Fool

AbbVie vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026? ↗

September 18, 2026

Via The Motley Fool

Bristol Myers Squibb to Report Results for Third Quarter 2026 on October 29, 2026

September 18, 2026

From Bristol Myers Squibb

Via Business Wire

Branded Pharmaceuticals Stocks Q2 Results: Benchmarking Supernus Pharmaceuticals (NASDAQ:SUPN)

September 17, 2026

Via StockStory

Bristol Myers Squibb Presents Sotyktu (deucravacitinib) Data Showing Durable Efficacy, Consistent Safety in Adults with Psoriatic Arthritis Over Two Years

September 17, 2026

From Bristol Myers Squibb

Via Business Wire

Bristol Myers Squibb Announces Dividend

September 16, 2026

From Bristol Myers Squibb

Via Business Wire

3 Healthcare Stocks That Fall Short

September 14, 2026

Via StockStory

Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone? ↗

September 13, 2026

Via The Motley Fool

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

September 10, 2026

Via Investor Brand Network

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

Via Investor Brand Network

MissionIRNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) Advances Lucid-MS Toward Phase 2 Trial Following FDA Clearance

September 10, 2026

Via Investor Brand Network

Historic First in MS Treatment Could Reshape a Multibillion-Dollar Therapeutics Market

September 10, 2026

From BioMedWire

Via GlobeNewswire

Frequently Asked Questions

Is Bristol-Myers Squibb publicly traded?

Yes, Bristol-Myers Squibb is publicly traded.

What exchange does Bristol-Myers Squibb trade on?

Bristol-Myers Squibb trades on the New York Stock Exchange

What is the ticker symbol for Bristol-Myers Squibb?

The ticker symbol for Bristol-Myers Squibb is BMY on the New York Stock Exchange

What is the current price of Bristol-Myers Squibb?

The current price of Bristol-Myers Squibb is 61.46

When was Bristol-Myers Squibb last traded?

The last trade of Bristol-Myers Squibb was at 10/01/26 04:10 PM ET

What is the market capitalization of Bristol-Myers Squibb?

The market capitalization of Bristol-Myers Squibb is 136.57B

How many shares of Bristol-Myers Squibb are outstanding?

Bristol-Myers Squibb has 137B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.